XML 49 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business combination - Narratives (Details) - ARIAD Pharmaceuticals
$ in Millions
Jun. 01, 2016
USD ($)
Business combinations  
Upfront Payment $ 147.5
Fair value of consideration transferred  
Fair value of consideration transferred 440.5
Cash 147.5
Contingent consideration $ 293.0
Contingent Consideration  
Fair value of consideration transferred  
Probability of technical success (“PTS”) (as a percent) 25.00%
Projected cash flows period 18 years
Discount rate (as a percent) 10.00%
Minimum  
Business combinations  
Royalties paid (as a percentage) 32.00%
Maximum  
Business combinations  
Royalties paid (as a percentage) 50.00%
Potential future oncology development and regulatory approval milestone payments $ 135.0
Development costs $ 7.0